Warrant overhang (19.2M total, vs 18M shares issued) will cap upside and pressure the stock toward the C$1.00 offering level near-term. Monitor for TSXV final approval and potential secondary share pressure as freely-tradable units enter the market (Canadian purchasers' shares and warrants are immediately tradable). Catalyst potential from Albany PEA (summer 2026) and ZenGUARD pilot are long-dated; near-term price action likely driven by dilution absorption and warrant delta hedging.
Price Chart
Executive Summary
Zentek closed a fully-subscribed brokered LIFE offering for gross proceeds of C$18M (18M units at C$1.00/unit), with each unit comprising one common share and a five-year warrant exercisable at C$1.50. Proceeds are earmarked for Albany Graphite project development (PEA, feasibility studies), ZenGUARD commercialization, and working capital. The offering represents ~28% dilution to the pre-offering share count (~65M shares outstanding implied by $65M market cap at ~$1.00/share), plus additional warrant overhang.
Key Facts
- Gross proceeds raised: C$18M via 18M units at C$1.00/unit
- Each unit: 1 common share + 1 warrant (C$1.50 exercise, 5-year term, exp. May 27, 2029)
- Warrant overhang: 18M common shares + 1.197M broker warrants exercisable at C$1.00
- Insiders purchased 695,000 units (3.9% of offering); subject to hold period until Sep 28, 2026
- Broker (Red Cloud) received C$1.197M cash fee and 1.197M broker warrants
- Offering price (C$1.00) represents ~100% of pre-offering market price (implied ~$1.00/share from $65M cap)
- Use of proceeds: Albany Graphite PEA & feasibility, ZenGUARD commercialization, working capital
- Closing is 6 days after the Offering Document date (May 14); shares not registered under US Securities Act
- Filing type: 6-K (foreign private issuer report) with cross-filing amplifier verdicts for activist/offering/annual context
Financial Impact
~28% dilution from 18M new shares against ~65M pre-offering float; total share count pro forma ~83M, plus 19.2M total warrants (18M unit warrants + 1.2M broker warrants) creating ~23% additional overhang if exercised
Risk Factors
- Near-term price pressure from ~28% dilutive share issuance plus 19.2M warrant overhang
- Warrants exercisable at C$1.50 (50% premium) limit upside; unlikely to be exercised near-term
- Company has no current revenue generation; reliance on future development milestones for value creation
- TSXV final approval still pending, creating residual execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001062993-26-002893 |
| Document: form6k.htm | 0001062993-26-002893 |
| Document: 0001062993-26-002893-index-headers.html | 0001062993-26-002893 |
| Document: 0001062993-26-002893-index.html | 0001062993-26-002893 |
| Document: 0001062993-26-002893.txt | 0001062993-26-002893 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | 6-K | — | awaiting T+20 | — | — |
Aug 31, 2026 8w ago | 6-K | $0.5180 | awaiting T+20 | — | — |
Aug 28, 2026 8w ago | 6-K | $0.5200 | awaiting T+20 | — | — |
Aug 21, 2026 9w ago | 6-K | $0.6030 | awaiting T+20 | — | — |
Aug 20, 2026 9w ago | 6-K | $0.6049 | awaiting T+20 | — | — |
Aug 10, 2026 11w ago | 6-K | $0.6757 | awaiting T+20 | — | — |
Jul 20, 2026 14w ago | 6-K | $0.4601 $0.5950 | ▲ +29.32% | ▲ +25.20% | — |
Jul 15, 2026 14w ago | 6-K | $0.4950 $0.6292 | ▲ +27.11% | ▲ +24.77% | — |
Jul 7, 2026 16w ago | 6-K | $0.5138 $0.6739 | ▲ +31.16% | ▲ +29.83% | — |
Jun 29, 2026 17w ago | 6-K | $0.4620 $0.5316 | ▲ +15.06% | ▲ +15.34% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers